Annual Meeting - Nov. 8-10

SITC 2024 Annual Meeting Schedule

Friday, Nov. 8–Sunday, Nov. 10

Welcome to our 39th Annual Meeting. You can view the entire Annual Meeting schedule below.

Register NowPre-Conference ScheduleAbstract Information

Friday, Nov. 8, 2024

39th Annual Meeting   |   George R. Brown Convention Center  |   7:45 a.m.–7 p.m. CST

Times and program schedules subject to change.


Session 100: Presidential Welcome

7:45-7:50 a.m.  CST  |  George R. Brown Convention Center - Level 3 - Hall A3

Chair: 

Leisha Emens, MD, PhD


 

View Full Session Schedule

7:45 a.m. Presidential Welcome
Leisha Emens, MD, PhD

Session Description

SITC President Leisha Emens, MD, PhD will welcome attendees for the official start of the 39th Annual Meeting.


Session 101: Awards Ceremony 1

7:50-8:20 a.m.  CST |  George R. Brown Convention Center - Level 3 - Hall A3

Chair: 

Leisha Emens, MD, PhD


 

View Full Session Schedule

7:50 a.m. Introduction
Leisha Emens, MD, PhD
7:55 a.m. TBA

Session Description

The Awards Ceremony will recognize annual award recipients, presented by SITC President Leisha Emens, MD, PhD.


Session 102: Keynote Adress

8:20-9:10 a.m.  CST  |  George R. Brown Convention Center - Level 3 - Hall A3

Chair: 

Leisha Emens, MD, PhD


 

View Full Session Schedule

8:20 a.m. Introduction
Leisha Emens, MD, PhD 
8:25 a.m. Origin and Differentiation of Stem-like CD8 T cells in Chronic Infection and Cancer
Rafi Ahmed, PhD, FAIO - Emory University School of Medicine

Session Description

Coming Soon

Break

9:10–9:40 a.m. CST  


Session 103: Pre-malignancy Biology Driving Precision Prevention and Interception Immunotherapy

9:40–11:45 a.m.  CST  | George R. Brown Convention Center -Level 3 - Hall A3

Co-Chairs: 

Olivera Finn, PhD, FAIO
University of Pittsburgh

Elizabeth Jaffee, MD, FAIO
Sidney Kimmel Cancer Center, Johns Hopkins University

View Full Session Schedule

9:40 a.m. Introduction
TBA 
9:50 a.m.
Immune Recognition of Germline Neoantigens
Christina Curtis, PhD, MSc – Stanford University
10:15 a.m.
Biology of Pre-Malignancy and Inflammation -3-D Imaging
Peter Sorger, PhD - Harvard Medical School
10:40 a.m.
Preventive Vaccines 
Napoor Raje, MD - Massachusetts General Hospital
11:05 a.m.
Immune Contexture of Premalignant Lesions

Jerome Galon, PhD - INSERM, Sorbonne Universites Paris

11:30 a.m. Abstract Presentation
TBA 

Session Description

Many important discoveries in immunology over the last several decades have been applied to the cancer problem with the goal of making immune rejection of cancer more effective. This knowledge has resulted in the development of highly effective cancer immunotherapies for patients with advanced disease. Relatively little of this knowledge has translated into efforts to strengthen cancer immunosurvellance to prevent or intercept cancer development. Vaccines have successfully prevented virus-associated cancers including cervical and hepatocellular carcinomas. At this time of rising cancer rates in young adults, vaccines targeting the earliest changes in premalignacy are urgently needed. This session will highlight research leading us in this new direction. 


Session 104: Late Breaking Abstract Session 

The LBA Session will feature Late-Breaking Abstracts – Clinical Only (LBAs) for abstracts with late-breaking data from interventional clinical trials in humans. For more information about LBAs, click here.

11:45 a.m.–12:15 p.m. CST  |  George R. Brown Convention Center -Level 3 - Hall A3

Chair: 

Alfred L. Garfall, MD
Hospital of the University of Pennsylvania

View Full Session Schedule

11:45 a.m. Coming Soon
TBA

Session Description

This 30-minute session will highlight two selected Late-breaking Abstracts who will each showcase their work in a 15-minute oral presentation.  

Lunch and Poster Viewing

12:15–1:45 p.m. CST  | George R. Brown Convention Center -Level 1 -Exhibit Halls AB


Concurrent Session 105a: Rapid Oral Abstract-Basic

12:30–1:30 p.m. CST |  George R. Brown Convention Center - Level 3 -  Grand Ballroom B

Co-Chairs: 

Sarah B. Gitto, PhD
University of Pennsylvania

Geoffrey Markowitz, PhD
Weill Cornell Medicine

View Full Session Schedule

12:30 p.m. Coming Soon
TBA

Session Description

This fast-paced session will feature six oral presentations from select basic science abstracts with time for Q&A.  


Concurrent Session 105b: Rapid Oral Abstracts - Clinical

12:30–1:30 p.m. CST |  George R. Brown Convention Center - Level 3 - Grand Ballroom C

Co-Chairs: 

Zachary A. Cooper, PhD
AstraZeneca

Robyn Gartrell, MD
Johns Hopkins School of Medicine

View Full Session Schedule

12:30 p.m. Coming Soon
TBA

Session Description

This fast-paced session will feature six oral presentations from select clinical abstracts with time for Q&A. 


Concurrent Session 106a: Leveraging B Cells for Anti-Tumor Immunity 

1:45–3:20 p.m. CST  | George R. Brown Convention Center - Level 3 - Hall A3

Co-Chairs: 

Tullia Bruno, PhD
University of Pittsburgh

Daniel Hollern, PhD 
Salk Institute 

View Full Session Schedule

1:45 p.m. Intro to B Cells and Outside of TLS 
Tullia Bruno, PhD - University of Pittsburgh, Pennsylvania
1:55 p.m. Modulation of B cells via CD40
Daniel Hollern, PhD - Salk Institute
2:20 p.m. Regulatory B Cells
Yuliya Pylayeva-Gupta, PhD - UNC Lineberger Comprehensive Cancer Center
2:45 p.m. B Cells Checkpoint
Lloyd Bod, PhD - Massachusetts General Cancer Center
3:10 p.m. Abstract Presentation
TBA

Session Description

Coming Soon


Concurrent Session 106b: Microbiome: Ready for Prime Time?

1:45–3:20 p.m. CST  |  George R. Brown Convention Center - Level 3 - General Assembly Theater

Co-Chairs: 

Bertrand Routy, MD, PhD
CHUM Research Centre 

Jennifer Wargo, MD, MMSC
The University of Texas MD Anderson Cancer Center

View Full Session Schedule

1:45 p.m. Introduction
Co-Chair
1:47 p.m. Targeting the Microbiome in GVHD and GVL
Jonathan Peled, MD, PhD - Memorial Sloan Kettering Cancer Center
2:02 p.m. Bugs as Drugs
Christopher Johnston, PhD - Fred Hutchinson Cancer Center
2:17 p.m.

Profiling and Modulating the Microbiome in Cancer
Lisa Derosa, PhD -  Gustave Roussy

2:32 p.m.

Ongoing Trial
Arielle Elkrief, MD, FRCPC - University of Montréal Research Center

2:47 p.m. Abstract Presentation
TBA
2:57 p.m. Abstract Presentation
TBA
3:07 p.m. Panel Discussion and Q&A 

Session Description

Session Title: Microbiome: Ready for Prime Time in immuno-oncology?

In less than a decade, several discoveries propelled the gut microbiome from the dark matter to one of the “hallmarks of cancer”. Recent studies revealed that the baseline microbiome composition correlated with the anti-cancer response, the risk of immune-related toxicities and the development of graft-versus-host disease (GVHD). This intricate relationship is linked through several mechanisms including microbiome-associated molecular patterns, cross-reactive antigens, bacterial metabolites and immune checkpoint expression.

Furthermore, harnessing the microbiome using fecal microbiota transplantation, probiotics and prebiotics demonstrated that shifting the microbiome composition can enhance immune checkpoint inhibitors (ICI) response and improve GVHD. In this session, we will focus on the development of user-friendly strategies to profile microbiome composition as a novel biomarker. We will review the ongoing strategies to improve the microbiome composition for patients amenable to ICI treatment or allogeneic stem cell transplantation. In sum, the aim of this session is to understand and review the mechanisms by which bugs can become new cancer drugs.


Concurrent Session 106c: NK Cells and Innate Immunity

1:45–3:20 p.m. CST  |  George R. Brown Convention Center - Level 3 - Grand Ballroom A

Co-Chairs: 

Katy Rezvani, MD, PhD
The University of Texas MD Anderson Cancer Center

Eric Vivier, DVM, PhD
Aix Marseille University

View Full Session Schedule

1:45 p.m. Introduction
TBA  
1:46 p.m. Innate Immunity - NK Cells and ILCs
Marco Colonna, MD - Washington University School of Medicine, St. Louis 
2:08 p.m. TBA
Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
2:30 p.m. TBA
Eric Vivier, DVM, PhD – Aix Marseille University
2:52 p.m.

Cytokine Signaling and Their Therapeutic Targeting in NK Cells
Nicholas Huntington, PhD – Monash University

3:05 p.m. Panel Discussion  

Session Description

Natural Killer (NK) cells and Type 1 Innate Lymphoid Cells (ILCs) play a critical role in the innate immune response by detecting and destroying neoplastic cells independently of prior antigen exposure. Their therapeutic modulation represents an emerging frontier in cancer immunotherapy.

In this session at the SITC conference Dr. Marco Colonna will provide a detailed overview of ILCs, highlighting their potential in cancer immunotherapy. Dr. Rezvani will present on the engineering of NK cells, discussing the latest strategies and preclinical evidence that underscore the translation of this strategy to the clinic. Dr. Eric Vivier will present on the application of NK cell multi-specific engagers, focusing on their design, mechanism of action, and their evolving role in the targeted treatment of cancer. Each presentation aims not only to educate but also to encourage dialogue on how these innovations can be best integrated and optimized within current clinical frameworks.


Concurrent Session 106d: Biotech Breakthroughs - Solid Tumor IO at the Tipping Point

1:45–3:20 p.m. CST  |  George R. Brown Convention Center - Level 3 - Grand Ballroom B

Co-Chairs: 

Kristen Hege, MD

Zhen Su, MD, MBA
Marengo Theraputics

View Full Session Schedule

1:45 p.m. Intro: Highlight FDA Approvals 
Co-Chair
1:50 p.m. TILs
Raj Puri, MD - Iovance Biotherapeutics
2:05 p.m. TCR Engineered T Cells
Jo Brewer, PhD - Adaptimmune
2:20 p.m. DLL3 T Cell Engager
Pablo Martinez, MD, PhD - Amgen
2:35 p.m.

Abstract Presentation
TBA

2:45 p.m. Abstract Presentation
TBA
2:55 p.m.

Panel Discussion: IO for Solid Tumors Beyond Checkpoint Inhibitors – Future Directions

Kristen Hege, MD
Zhen Su, MD, MBA - Marengo Therapeutics
Raj Puri, MD, PhD - Iovance Biotherapeutics
Jo Brewer, PhD Adaptimmune 
Pablo Martinez, MD PhD - Amgen
William Grossman, PhD, MD - Gilead
Brad Loncar, BBA - BiotechTV
Allison Betof Warner, MD, PhD - Stanford University School of Medicine

Session Description

Cancer immunotherapy has transformed cancer care over the past decade with more than 25 FDA approved medicines in the clinic. Immune activation focused novel modalities have demonstrated compelling efficacy and achieved regulatory approvals in hematologic malignancies over the past decade. Beyond the first wave T cell checkpoint blockade, developing next wave novel IO therapeutics in solid tumor have been challenging, but the tide has turned. 2024 is a breakthrough year for new and pending FDA approvals of both cell therapies and complex biologics in multiple solid tumor indications focusing on reinvigorating the anti-tumor immune response. In this session you will learn about the development and commercial launch of these exciting new immuno-oncology products including tumor infiltrating lymphocytes, T cell receptor engineered T cells, T cell engaging bispecific antibodies, next generation cytokines and more.


Concurrent Session 106e: Commonalities and Site-Specific Factors for Immune Microenvironments across and between Tumor Types

1:45–3:20 p.m. CST  | George R. Brown Convention Center - Level 3 - Grand Ballroom C

Co-Chairs: 

F. Stephen Hodi Jr., MD
Dana-Faber Cancer Institute

Mario Sznol, MD
Yale School of Medicine

View Full Session Schedule

1:45 p.m. Immune Monitoring
Padmanee Sharma, MD, PhD - The University of Texas MD Anderson Cancer Center
2:05 p.m. How Tumors are Similar or Different in Terms of Their Microenvironments
Alexis Combes, PhD - University of California, San Francisco
2:25 p.m. Computational Biology
Aaron Newman, PhD - Stanford University
2:45 p.m. Pathology
Wolf H. Fridman, MD, PHD - Cordeliers Research Centre
3:05 p.m.

Abstract Presentation
TBA

Session Description

In humans, the immune component of the tumor microenvironment is likely shaped over many years. Tumor genetics and epigenetics, host genetics, and a lifetime of acute and chronic environmental exposures likely contribute to the immune composition of the tumor. These factors influence the natural history of the malignancy and its response to all forms of therapy including immune modulation. Recent data suggest that tumor immune microenvironments can be grouped into a limited number of phenotypes which could provide insights into pathogenesis and approaches to treatment. In this session, speakers will describe the spectrum of tumor immune microenvironments as revealed by analyses of histopathology, sequencing, and immune monitoring, characterizing commonalities and site-specific differences as they relate to the primary tumor site and/or site of metastases.

Break

3:20–3:50 p.m. CST  


Concurrent Session 107a: Cellular Therapies/Regulatory/Manufacturing

3:50–5:25 p.m. CST  |  George R. Brown Convention Center - Level 3 - Hall A3

Co-Chairs: 

Chantale Bernatchez, PhD
Cell Therapy Manufacturing Center 

Patrick Hanley, PhD
Children's National Hospital

Raj Puri, MD, PhD
Iovance Biotheraputics

View Full Session Schedule

3:50 p.m. Introduction
TBA                               
3:55 p.m.

Release Criteria Summit Update 

Michael Kalos, PhD - CTRL Therapeutics
4:20 p.m. Point of Care Manufacturing
Yongping Wang, MD, PhD - Children's Hospital of Philadelphia
4:40 p.m. Iovance Experience with Regulatory Approval of TIL Product
Arvind Natarajan, PhD - Iovance Biotherapeutics

5 p.m.

Panel Discussion

Chantale Bernatchez, PhD - Cell Therapy Manufacturing Center
Patrick Hanley, PhD - Children's National Hospital
Raj Puri, MD, PhD - Iovance Biotherapeutics
Michael Kalos, PhD - CTRL Therapeutics
Yongping Wang, MD, PhD - Childrens Hospital of Philadelphia 
Arvind Natarajan, PhD - Iovance Biotherapeutics
Agnes Yeboah, PhD - Bristol Myers Squibb
Mathew Klinker, PhD - U.S. Food and Drug Administration

Session Description

Cellular therapies offer great promise as a cancer therapy. They are living biological drugs, and often personalized, which gives them unique properties, characteristics, and great variability. These factors have made adhering to existing regulatory requirements challenging and requires significant collaboration and interactions with the FDA and other health authorities. Commercializing approved cellular therapies requires novel strategies for adoption, patient access, and cost. Though in early stages, new paradigms for manufacturing and delivery of autologous cell therapies, namely point of care manufacturing, have emerged that may reduce cost to manufacture and increase patient access. Collaboration with health authorities is critical for point of care manufacturing to have regulatory success. This session will first provide an update on SITC’s Release Criteria Summit. During the one-day virtual summit, topics include stakeholder feedback, summaries, current state, and future directions identified during the one-day virtual summit. The session will then expand upon some of the concepts discussed during the release criteria summit and we will hear about Iovance Biotherapeutics’s experience with regulatory approval of the first and only FDA-approved T cell therapy for a solid tumor indication. Finally, we will hear about how new manufacturing strategies are being developed to reduce costs and increase access for patients and discussion on regulatory perspectives. 


Concurrent Session 107b: Protein and Cellular Engineering Strategies

3:50–5:25 p.m. CST  |  George R. Brown Convention Center - Level 3 - General Assembly Theater

Co-Chairs: 

Marion Alcantara, MD, PhD
Institut Curie, Paris

Cristina Puig-Saus, PhD
UCLA        

View Full Session Schedule

3:50p.m. Introduction 
Session Co-Chair 
3:55 p.m. Genome Engineering
Justin Eyquem, PhD - University of California, San Francisco
4:15 p.m. Protein Engineering
Marcela Maus, MD, PhD - Massachusetts General Hospital
4:35 p.m. Protein Engineering 
Yvonne Chen, PhD - University of California, Los Angeles
4:55 p.m.

Abstract Presentation
TBA 

5:10 p.m. Abstract Presentation
TBA 

Session Description

Cell and gene therapies have made a great breakthrough in the immuno-oncology field. Technological advances have created opportunities for genetically engineered immune cells to be “redirected” against tumor cells. As such, chimeric antigen receptor (CAR)-T cells are now part of the routine clinical care for many hematological malignancies, but improvements are still needed. A better understanding of the mechanisms of action and the progress in molecular interventions are paving the way for the development of new generations of cellular immunotherapies. Innovative engineering methods will certainly lead to next-generation cell therapies with enhanced efficacy and/or reduced toxicity, notably for targeting low antigen-expressing tumors and solid cancers. This session will focus on genome and protein engineering strategies to optimize cell therapies for hematological and solid tumors.


Concurrent Session 107c: Timing and Combination of Systemic Therapies in Solid Cancers

3:50–5:25 p.m. CST  |  George R. Brown Convention Center - Level 3 - Grand Ballroom A

Co-Chairs: 

Diwakar Davar, MD
UPMC Hillman Cancer Center

Sherene Loi, MD, PhD
Peter MacCallum Cancer Centre

View Full Session Schedule

3:50 p.m.

Introduction
TBA
3:50 p.m. Potential Lessons for Other Tumor Types, Specially Renal Cell
Mike Atkins, MD, FAIO - Georgetown Lombardi Comprehensive Cancer Center

3:50 p.m. Innate Agonists
Janice M. Mehnert, MD - Perlmutter Cancer Center of NYU Langone Health
3:50 p.m. Combinations
Jason Luke, MD, FACP - UPMC Hillman Cancer Center
3:50 p.m. Abstract Presentation
TBA 
3:50 p.m. Abstract Presentation
TBA 

Session Description

This Session will explore how the underlying biology of combination therapies in solid tumors and how those combinations may change and overcome specific mechanisms of resistance to immune therapy in a spectrum of malignancies. The Session also aims to discuss provocative questions concerning novel combination immunotherapeutic development armed with a deeper biological understanding of how rational combinations and sequences of therapies can overcome specific resistance mechanisms, attendees will be equipped to design effective clinical trials leading to better patient outcomes.


Concurrent Session 107d: Oral Abstract Session

3:50–5:25 p.m. CST  | George R. Brown Convention Center - Level 3 - Grand Ballroom B

Co-Chairs: 

Roberta Zappasodi, PhD
Weill Cornell

Tanaya Shree, MD, PhD
Oregon Health and Sciences University

View Full Session Schedule

3:30 p.m. Coming Soon
TBA

Session Description

Selected abstracts will be presented in 10-15 minute oral presentations. 


Concurrent Session 107e: Immune Exclusion

3:50–5:25 p.m. CST  |  George R. Brown Convention Center - Level 3 - Grand Ballroom C

Co-Chairs: 

Christine Moussion, PhD
Genentech

Sara Pai, MD, PhD
Yale University School of Medicine

View Full Session Schedule

3:50 p.m. Introduction
Session Co-Chair
3:55 p.m.

Debate: Defining Immune Exclusion - Physical v. Functional
Physical: Ellen Pure, PhD - University of Pennsylvania: Argument for Physical Barrier 

Functional: G. Travis Clifton, MD – Incendia Therapeutics: Argument for Functional Barrier 

4:25 p.m. Cross-talk Between Myeloid/Stroma/T Cells that Contributes to Immune Exclusion 
Brian Brown, PhD - Mount Sinai
4:45 p.m. Therapeutics that Target the Cross-talk
Akshay Krishnamurty, PhD - Genentech
5:05 p.m.

Abstract Presentation
TBA

5:20 p.m. Conclusion
Session Co-Chair

Session Description

Coming Soon


Concurrent Session 107f: Latin America Oral Abstract Session

3:50–5:25 p.m. CST  |  George R. Brown Convention Center - Level 3 - Meeting Room 332 | Download Flyer

Co-Chairs: 

Nora Sobrevilla, MD
Instituto Nacional de Cancerologia
Ana Anderson, PhD
Harvard Medical School

View Full Session Schedule

3:50 p.m. Coming Soon
TBA

Session Description

Coming Soon

Poster Reception 

5:30-7 p.m. CST  | George R. Brown Convention Center - Level 1 -Exhibit Halls AB

Saturday, Nov. 9, 2024

39th Annual Meeting   |   George R. Brown Convention Center   |   7:15 a.m.–8:30 p.m. CST

Times and program schedules subject to change.


Session 200: Business Meeting 

7:15–7:45 a.m. CST |  George R. Brown Convention Center - Level 3 - Hall A3

Chair: 

Leisha Emens, MD, PhD


 

View Full Session Schedule

7:15 a.m. Introduction
Leisha Emens, MD, PhD 
7:20 a.m. TBA

Session Description

Hear from SITC senior leadership about the strategic direction of the society and the potential opportunities for SITC members.


Session 201: Organizer Welcome

8–8:05 a.m. CT |  George R. Brown Convention Center - Level 3 - Hall A3

Chair: 

Harriet Kluger, MD
Yale University

View Full Session Schedule

8 a.m. Organizer Welcome
TBA

Session Description

The official start of the second full day begins with a welcome from one of the Organizers behind the Annual Meeting programming. 


Session 202: Richard V. Smalley Award and Lectureship

8:05–8:55 a.m. CST  |  George R. Brown Convention Center - Level 3 - Hall A3

Chair: 

Leisha Emens, MD, PhD


 

View Full Session Schedule

8:05 a.m. Introduction
TBA
8:10 a.m.

The Era of Cancer Vaccines Has Arrived

Elizabeth M. Jaffee, MD, FAIO, FAACR, FACP, FAAAS - Sidney Kimmel Cancer Center at Johns Hopkins

Session Description

Coming Soon


Session 203: Genomic Instability: How it Mediates Immunity and Immune Evasion

8:55–11 a.m. CST  |  George R. Brown Convention Center - Level 3 - Hall A3

Co-Chairs: 

David A. Braun, MD, PhD
Yale School of Medicine    

Stefani Spranger, PhD 
Koch Institute for Integrative Cancer Research at MIT

View Full Session Schedule

8:55 a.m. Introduction 
TBA
9 a.m. Clinical Aspects of Chromosomal Instability  
Samra Turajlic, MBBS, PhD - Francis Crick Institute
9:20 a.m. Abstract Presentation 
TBA
9:32 a.m. Q&A
9:40 a.m. Chromosomal Instability as a Mechanism of Immune Evasion 
Samuel Bakhoum, MD, PhD - Memorial Sloan Kettering Cancer Center
10 a.m.

Abstract Presentation 
TBA

10:12 a.m. Q&A
10:20 a.m. Interferon Biology Alongside Cancer Progression and Therapeutic Resistance  
Andy Minn, MD, PhD - University of Pennsylvania
10:40 a.m. Abstract Presentation 
TBA
10:52 a.m. Q&A

Session Description

Genomic instability is a core feature of cancer evolution, but beyond tumor-intrinsic effects, it can also contribute to pro- or anti-tumor immune responses. Genomic instability leading to DNA damage and mutations increase the potential neoantigen burden and may therefore contribute positively to anti-tumor immunity. By contrast, chromosomal instability may lead to chronic activation of innate and adaptive immune pathways, ultimately mediating immune evasion by tumor cells. This session will focus on the role of understanding chromosomal instability in cancer evolution in the clinic, and then dive into the mechanistic underpinnings of how chromosomal instability and chronic interferon signaling may facilitate immune evasion and resistance to current immunotherapies. 

Break

11–11:15 a.m. CST  


Fireside Chat

11:15–11:45 a.m. CST | George R. Brown Convention Center - Level 3 - Hall A3

Chair: 

Leisha Emens, MD, PhD


View Full Session Schedule

11:15 a.m. TBA
Kim Rathmell, MD, PhD - National Cancer Institute

Session Description


Session 204:  Late-Breaking Abstract Session 

The LBA Session will feature Late-Breaking Abstracts- Clinical Only (LBAs) for abstracts with late-breaking data from interventional clinical trials in humans. For more information about LBAs, click here.

11:45 a.m.–12:15 p.m. CST |  George R. Brown Convention Center - Level 3 - Hall A3

Chair: 

Aurélien Marabelle, MD, PhD 
Gustave Roussy


View Full Session Schedule

11:45 a.m. Coming Soon
TBA

Session Description

This 30-minute session will highlight two selected Late-breaking Abstracts who will each showcase their work in a 15-minute oral presentation.  

Lunch and Poster Viewing 

12:15–1:45 p.m. CST  |  George R. Brown Convention Center - Level 1 - Exhibit Halls AB


Session 205a: Rapid Oral Abstract-Basic 

12:30–1:30 p.m. CST |  George R. Brown Convention Center - Level 3 - Grand Ballroom B

Co-Chairs: 

Nicole Scharping, PhD
University of California, San Diego


Aleksei Tikhonov, PhD
Gustave Roussy

View Full Session Schedule

12:30 p.m. Coming Soon
TBA

Session Description

This fast-paced session will feature six oral presentations from select basic science abstracts with time for Q&A.  


Session 205b: Rapid Oral Abstract-Clinical 

12:30–1:30 p.m. CST |  George R. Brown Convention Center - Level 3 - Grand Ballroom C

Co-Chairs: 

Golnaz Morad, DDS, PhD
The University of Texas MD Anderson Cancer Center


Tanya Keenan, MD, MPH
Merck

 

View Full Session Schedule

12:30 p.m. Coming Soon
TBD

Session Description

This fast-paced session will feature six oral presentations from select clinical abstracts with time for Q&A. 


Session 206: Presidential Session 

1:45–3:10 p.m. CST |  George R. Brown Convention Center - Level 3 - Grand Ballroom C

Chair: 

Leisha Emens, MD, PhD


 

View Full Session Schedule

1:45 p.m. Introduction
TBA

Session Description

Coming Soon

Break

3:10–3:25 p.m. CST 


Session 207a: CD4 & Tregs

3:25–4:45 p.m. CST | George R. Brown Convention Center - Level 3 - Hall A3

Co-Chairs: 

Lawrence Fong, MD 
Fred Hutchinson Cancer Center

Sergio A. Quezada, PhD 
University College London

View Full Session Schedule

3:25 p.m. Role of CD4 T Cells in Tumor Immunology
Session Co-Chair
3:30 p.m. Tumor Antigen Recognition by CD4 T Cells 
Cathy Wu, MD - Dana-Farber Cancer Institute
3:50 p.m. Targeting Regulatory CD4 T Cells
Aurélien Marabelle, MD, PhD  – Gustave Roussy
4:10 p.m. CD4 CAR T Cells 
Joseph Melenhorst, PhD - Cleveland Clinic
4:30 p.m. Abstract Presentation 
TBA

Session Description

Explore the different roles CD4+ T cells play in tumor immunity. Topics will include antigen recognition, regulatory T cells, and the importance of CD4+ CAR T cells.


Session 207b: Everything but the Cell: Priming Patients for T Cell Administration  

3:25-4:45 p.m. CST |  George R. Brown Convention Center - Level 3 - General Assembly Theater

Co-Chairs: 

Stephanie Goff, MD, FACS 
National Cancer Institute  

Marco Ruella, MD
University of Pennsylvania

View Full Session Schedule

3:25 p.m. Background on Lymphodepletion, and Experience with TILs
Stephanie Goff, MD, FACS - National Cancer Institute
3:45 p.m. Lymphodepletion before CAR-, TCR- T Cell Therapies 
Marco Ruella, MD - University of Pennsylvania
4:05 p.m. Lymphodepletion: Mechanisms and Preclinical Models
Chrystal Paulos, PhD - Winship Cancer Institute at Emory University 
4:25 p.m. Novel, Future Strategies for Safer and Effective Lymphodepletion 
Q&A; Panel Discussion

Session Description

This session delves into the critical role of lymphodepletion as a preparatory step in adoptive T-cell therapies. The speakers will explore the foundations, current practices, and future directions of lymphodepletion strategies to optimize the efficacy of T-cell administration in cancer treatment. Dr. Goff will provide an insightful overview of lymphodepletion, sharing her extensive experience with tumor-infiltrating lymphocytes (TILs) and early CAR-T. This talk will highlight key clinical outcomes and lessons learned from pioneering treatments at the National Cancer Institute. Dr. Ruella will discuss the specific applications of lymphodepletion in CAR-T and TCR-engineered T-cell therapies. His presentation will cover the practical aspects of patient preparation, focusing on optimizing treatment efficacy and patient safety. Dr. Paulos will delve into the mechanistic insights and the importance of preclinical models in understanding lymphodepletion. Her talk aims to bridge the gap between laboratory findings and clinical applications, providing a robust scientific foundation. Lastly, the panel discussion will explore emerging strategies and innovations designed to enhance the safety and effectiveness of lymphodepletion. The session will examine potential advancements that could revolutionize how patients are prepared for adoptive T-cell therapies. Attendees will gain a comprehensive understanding of the various facets of lymphodepletion, including current techniques, challenges, and innovative approaches on the horizon. This session is designed for clinicians, researchers, and healthcare professionals involved in the field of cancer immunotherapy, offering critical insights that could shape future treatment protocols.


Session 207c: Biomarkers Guiding Design of T Cell Therapies 

3:25–4:45 p.m. CST |  George R. Brown Convention Center - Level 3 - Grand Ballroom A

Co-Chairs: 

James Yang, MD
The National Cancer Institute

Simon Turcotte, MD, MSc, FRCSC
Universite de Montreal

View Full Session Schedule

3:25 p.m. Single Cell Sequencing Data and Multiple IF and Analyses Shown in Recent Publications
George Coukos, MD, PhD - Ludwig Cancer Research Lausanne Branch
 3:45 p.m. Biomarkers of Efficacy for Epithelial Cancer TIL and Trial Design
TBA
 4:05 p.m. Circulating DNA as a Endpoint for Cell Therapy or Immune Checkpoint Inhibitors
Valsamo Anagnostou, MD, PhD - Johns Hopkins University
  4:25 p.m. Abstract Presentation
TBA
  4:35 p.m. Abstract Presentation
TBA

Session Description

Coming Soon 


Session 207d: Oral Abstract Session 

3:25–4:45 p.m. CST |  George R. Brown Convention Center - Level 3 - Grand Ballroom B

Co-Chairs: 

Katie Campbell, PhD
University of California, Los Angeles

Mathieu Rouanne, MD, PhD
Columbia University

 

View Full Session Schedule

3:20 p.m. Coming Soon
TBA

Session Description

Selected abstracts will be presented in 10-15 minute oral presentations. 


Session 207e: Modulating the Tumor Vasculature to Improve Immunotherapy

3:25–4:45 p.m. CST |  George R. Brown Convention Center - Level 3 -Grand Ballroom C

Co-Chairs: 

Edda Sciutto, PhD
Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico

Sabina Signoretti, MD
Brigham and Women's Hospital



View Full Session Schedule

3:25 p.m.

Tumor Vasculature to Improve Immunotherapy 

Amanda Lund, PhD - NYU Grossman School of Medicine
3:45 p.m.

Tumor Vasculature to Improve Immunotherapy 

Mahrukh Huseni, PhD - Genentech
4:05 p.m.

Tumor Vasculature to Improve Immunotherapy 

Anna Dimberg, MSc, PhD - Uppsala University
4:25 p.m.

Abstract Presentation

TBA
4:35 p.m.

Abstract Presentation

TBA

Session Description

Blood and lymphatic vessels are essential for oxygen and nutrient delivery, removal of waste products, and control of immune responses to maintain normal tissue homeostasis. The rapid formation of tumor tissues requires an accelerated vascularization process that leads to a dysfunctional blood and lymphatic vessel network. This abnormal tumor vasculature contributes to the creation of a hypoxic and acidic tumor microenvironment, which facilitates cancer cells growth and metastatic dissemination, and also limits the infiltration of immune cells and their anti-tumor activity.  

New approaches aimed at modulating the tumor vasculature represent a promising strategy to maximize patient response to cancer treatments. This session will focus on exciting findings obtained by targeting blood and lymphatic vessels to increase the efficacy of immunotherapy in various cancer types.   

Break

4:45–5:15 p.m. CST  


Session 208a: The Yin and Yang of Myeloid Cells

This session is co-organized by the Society for Immunotherapy of Cancer (SITC) and The Myeloid Network.

5:15–6:35 p.m. CST |  George R. Brown Convention Center - Level 3 - Hall A3

Co-Chairs: 

Jennifer Guerriero, PhD 
Brigham and Women's Hospital


Alberto Mantovani, MD 
Instituto Clinico Humanitas

View Full Session Schedule

5:15 p.m. Macrophages
Renato Ostuni, PhD - Vita-Salute San Raffaele University
5:35 p.m. Dendritic Cells
Miriam Merad, MD, PhD -  Icahn School of Medicine at Mount Sinai
5:55 p.m. Neutrophils
Lai Guan Ng, PhD - Shanghai Immune Therapy Institute
6:15 p.m. Abstract Presentation
TBA
6:25 p.m.  Abstract Presentation
TBA

Session Description

Myeloid cells are a major component of the tumor microenvironment (TME) and can promote tumor progression and resistance to immunotherapy; conversely, they can also contribute to anti-tumor responses. This program will explore the opposing roles (ie the Yin and Yang) of myeloid cells. This program will explore the recent advances in the field including underlying biology and diversity of myeloid cells, myeloid signaling pathways, regulation of myeloid cells and therapeutic approaches to target myeloid cells in immuno-oncology. The session aims to bring the field together to educate and promote myeloid cell targeting with the overall goal of making the TME more permissive and expanding tumor specific T cells. This session is relevant to basic, translational, and clinical researchers and physicians and will provide an overview of the diversity, functions and therapeutic targeting of myeloid cells in cancer. 


Session 208b: Cellular Therapies - Financial Toxicities, Access to Care 

5:15–6:35 p.m. CST |  George R. Brown Convention Center - Level 3 - Grand Ballroom B

Co-Chairs: 

Nirav Shah, MD, MSHP 
Medical College of Wisconsin

Anna Sureda, MD, PhD
Barcelona Hematology Institute

View Full Session Schedule

5:15 p.m. Financial Toxicity, CAR T Therapies 
Nandita Khera, MD, M.P.H - Mayo Clinic       
5:35 p.m. Manufacturing Models, Alternative Manufacturing Models, and Accessibility 
Nirav Shah, MD - Medical College of Wisconsin
5:55 p.m. Racial, Ethnic, and Socioeconomic Disparities in Access to Care
Anurekha Hall, MD, MS – Seattle Childrens 
6:15 p.m. Abstract Presentation
TBA
6:25 p.m. Abstract Presentation
TBA

Session Description

Coming Soon


Session 208c: Evolution of Predictive Biomarkers in Immunotherapy: From Current State to Future Frontiers 

5:15–6:35 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom C

Co-Chairs: 

Alessio Cortellini, MD, PhD
Fondazione Policlinico Campus Bio-Medico & Campus Bio-Medico University & Department of Surgery and Cancer, Imperial College London                

Kerry L. Reynolds, MD
Massachusetts General Hospital 

View Full Session Schedule

5:15 p.m. Integrating Biomarkers for Personalized Immunotherapy
TBA
5:30 p.m. Current State of Biomarkers
Abdul Rafeh Naqash, MD - University of Oklahoma Medical Center
5:45 p.m.  Germline Status as Biomarkers for irAEs
Pauline Funchain, MD - Stanford University
6:00 p.m.  Model Systems as Biomarkers for Drug Development
Russel Jenkins, MD, PhD - Massachusetts General Hospital
6:15 p.m.  Abstract Presentation
TBA 
6:25 p.m.  Abstract Presentation
TBA 

Session Description

Coming Soon


Session 208d: CAR T and BiTEs in Heme Malignancies 

This session is co-organized by the Society for Immunotherapy of Cancer (SITC) and American Society of Hematology (ASH).

5:15–6:35 p.m. CST |  George R. Brown Convention Center - Level 3 - Grand Ballroom A

Co-Chairs: 

Natalie Grover, MD
University of North Carolina      

    
Aurélien Marabelle, MD, PhD
Gustave Roussy, France

View Full Session Schedule

5:15 p.m. Infection Risk of CAR Ts vs BiTEs 
Meera Mohan, MD, MS, FACP - Medical College of Wisconsin    
5:35 p.m. Abstract Presentation
TBA 
5:45 p.m.  Abstract Presentation
TBA 
5:55 p.m.  Drug Design, Optimization, Therapeutic Efficacy of CAR T vs Bispecifics
TBA
6:15 p.m.  Abstract Presentation
TBA 
6:25 p.m.  Abstract Presentation
TBA 

Session Description

Coming Soon


Session 208e: Oral Abstract Session 

5:15–6:35 p.m. CST | George R. Brown Convention Center - Level 3 -General Assembly Theater

Co-Chairs: 

Sandra Susanibar, MD
University of Pennsylvania    

 
Anusha Kalbasi, MD
Stanford



View Full Session Schedule

5:05 p.m. Coming Soon
TBA

Session Description

Selected abstracts will be presented in 10-15 minute oral presentations. 


Session 209: Awards Ceremony

6:40–7:10 p.m. CST |  George R. Brown Convention Center - Level 3 - Hall A3

Chair: 

Leisha Emens, MD, PhD


 

View Full Session Schedule

6:40 p.m. Introduction
Leisha Emens, MD, PhD 
6:45 p.m. TBA

Session Description

TBA

Poster Reception 

7:10-8:40 p.m. CST  | George R. Brown Convention Center - Level 1 - Exhibit Halls AB

The CheckPoints Party 

8:40 p.m.-Midnight CST  | Marriott Marquis - Level 2 - Houston Ballroom

Sunday, Nov. 10, 2024

39th Annual Meeting   |   George R. Brown Convention Center   |   8:15 a.m.–12:35 p.m. CST

Times and program schedules subject to change.


Session 300: Organizer Welcome   

8:15–8:20 a.m. CST |  George R. Brown Convention Center - Level 3 - Hall A3

Chair: 

Miriam Merad, MD, PhD
Icahn School of Medicine at Mount Sinai

View Full Session Schedule

8:15 a.m. Organizer Welcome
Miriam Merad, MD, PhD - Icahn School of Medicine at Mount Sinai

Session Description

The official start of the last day begins with a welcome from one of the Organizers behind the Annual Meeting programming


Session 301: Understanding Response and Resistance – Lessons from Patient Samples

8:20–10:30 a.m. CST | George R. Brown Convention Center - Level 3 - Hall A3

Co-Chairs: 

Antoni Ribas, MD, PhD
University of California, Los Angeles

Catherine Wu, MD
Dana-Farber Cancer Institute

View Full Session Schedule

8:20 a.m. Introduction
TBA
8:25 a.m. Understanding Immune Hubs to Improve Immunotherapy
Karin Pelka - University of California, San Francisco
8:55 a.m. TBA
Katie Campbell - University of California, Los Angeles
9:25 a.m. Abstract Presentation
TBA
9:40 a.m. Abstract Presentation
TBA
9:55 a.m. Abstract Presentation
TBA
10:10 a.m. Discussion
Antoni Ribas, MD, PhD - University of California, Los Angeles

Session Description

New single cell spatial pathology technologies are enabling a better understanding of the tumor microenvironment and how immune cells interact with cancer cells in response or resistance to cancer immunotherapies. The analysis of patient biopsy samples at unprecedented multidimensionality and resolution uncovers new biology and better understanding of how the immune system can treat cancer. In this session, two invited speakers that are at the forefront of the field will present analyses of patient biopsies, and three proffered speakers will be invited from the submitted abstracts that are thematically aligned with the session, followed by an expert discussion of the three oral presentations.

Break 

10:30-11 a.m. CST


Session 302: Hot Topic Symposium: AI in Discovery

11 a.m.–12:35 p.m. CST |  George R. Brown Convention Center - Level 3 - Hall A3

Co-Chairs: 

Riyue Bao, PhD
UPMC Hillman Cancer Center                    

Ira Mellman, PhD
Genentech  

View Full Session Schedule

11:00 a.m. Introduction
TBA
11:05 a.m. AI to Drive Clinical Transformation
X. Shirley Liu, PhD - GV20Theraputics
11:25 a.m. Macromolecule Discovery in the Age of AI 
TBA
11:45 a.m. The Evolution of AI in Drug Discovery: Hope vs. Reality 
TBA
12:05 p.m.
Panel Discussion

Session Description

Coming Soon